Melanoma (Skin) Clinical Trial
Official title:
Cytogenetic, Molecular and Cellular Biology Studies in Metastatic Melanoma Patients, Ancillary
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the
laboratory may help doctors learn more about changes that occur in DNA and identify
biomarkers related to cancer. It may also help doctors predict how patients will respond to
treatment.
PURPOSE: This laboratory study is assessing genes and immune response in tumor samples from
patients with locally advanced or metastatic melanoma.
OBJECTIVES:
- Characterize the frequency of non-random cytogenetic abnormalities in regional and
distant melanoma metastases and explore their association with clinical outcome of
patients with metastatic melanoma.
- Characterize the frequency of specific genetic alterations at either the DNA, mRNA, or
protein level and explore the association of these abnormalities with clinical outcome
in these patients.
- Characterize the host immunologic response to metastatic melanoma by determining whether
the in vivo pattern of cytokine expression is consistent with specific subsets of T
helper cells within melanoma deposits and to explore whether host immunologic response
varies based on the site of metastatic disease and/or correlates with clinical outcome
in these patients.
- Obtain peripheral blood, sera, and paraffin embedded tumor blocks from these patients.
- Correlate the most prevalent gene copy alteration observed in metastatic disease with
the risk of progression in tissue samples from patients registered on SWOG-9035 (primary
melanoma).
OUTLINE: Fresh and snap frozen tumor tissue samples are obtained from biopsy or surgical
procedures in the coordinated study. Specimens undergo mRNA and DNA analysis of tumor-related
genes and cytokine gene expression. Peripheral blood samples are obtained and processed for
sera and mononuclear cell testing. Tumor tissue samples embedded in paraffin or on unstained
slides are also obtained.
PROJECTED ACCRUAL: Approximately 120 patients will be accrued for this study within 3-4
years.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04062032 -
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
|
Phase 2 | |
| Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
| Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
| Completed |
NCT00962845 -
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
|
Early Phase 1 | |
| Completed |
NCT00324623 -
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma
|
Phase 1 | |
| Completed |
NCT00096382 -
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
| Completed |
NCT00104845 -
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 1 | |
| Completed |
NCT00089193 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 2 | |
| Completed |
NCT00072124 -
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
|
Phase 3 | |
| Completed |
NCT00072085 -
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT00039234 -
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
|
Phase 3 | |
| Completed |
NCT00042783 -
Vaccine Therapy in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
| Completed |
NCT00049010 -
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
|
N/A | |
| Completed |
NCT00005610 -
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
|
Phase 2 | |
| Completed |
NCT00006022 -
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
|
Phase 1 | |
| Completed |
NCT00006385 -
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
| Completed |
NCT00020358 -
Vaccine Therapy in Treating Patients With Melanoma
|
Phase 2 | |
| Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
| Withdrawn |
NCT00006126 -
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
|
Phase 1 |